Form 4: NeoGenomics General Counsel Sells Shares and Discloses Stock Options and Units

Alicia C. Olivo, General Counsel at NeoGenomics, sold 5,175 shares of common stock at $15.3575 per share and disclosed various stock options and restricted stock units.

Summary

• Alicia C. Olivo, the General Counsel of NeoGenomics, sold 5,175 shares of common stock at a price of $15.3575 per share on November 15, 2024.
• Following the transaction, Ms. Olivo directly owns 37,129 shares of NeoGenomics common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan.
• Ms. Olivo also holds a number of stock options, performance stock units, and restricted stock units, which vest over time and are tied to performance metrics.
• These holdings include options granted between 2019 and 2024, with various exercise prices and vesting schedules.
• The performance stock units are subject to the achievement of certain share growth and revenue goals.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of insider transactions. While the sale of shares could be seen as slightly negative, it was part of a pre-arranged plan and is not necessarily indicative of a negative outlook.

Positives

• The disclosure provides transparency into the holdings and transactions of a key executive.
• The use of a Rule 10b5-1 trading plan suggests a planned and orderly approach to stock sales.

Negatives

• The sale of shares by a key executive could be interpreted negatively by some investors, although it was part of a pre-arranged plan.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future performance, although this sale was part of a pre-arranged plan.
• The vesting of performance stock units is contingent on achieving specific share growth and revenue goals, which may not be met.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The vesting schedules for stock options and units are typical for executive compensation packages in the biotech and healthcare industries.
• Companies like Exact Sciences and Guardant Health also use similar equity-based compensation structures for their executives.

Stakeholder Impact

• Shareholders may be interested in the trading activities of company executives.
• The disclosure provides transparency into executive compensation and holdings.

Key Dates

Keywords

NeoGenomics, insider trading, stock options, restricted stock units, performance stock units, Rule 10b5-1, executive compensation, share sale, equity securities, General Counsel